September 2025
1. CHOON XY, Soh PJ, Hassan NA, Lim KS, et al
   Impact of Levetiracetam Cost on Epilepsy in a Resource-limited Country.
   Clin Neuropharmacol. 2025 Sep 11. doi: 10.1097/WNF.0000000000000656.
   

   >> Share

   
   July 2025
2. DOPP LM, Jung J, Markert OL, Frazier DL, et al
   Postictal Psychosis, a Case Report.
   Clin Neuropharmacol. 2025 Jul 10. doi: 10.1097/WNF.0000000000000644.
   

   >> Share

   
   
3. RETTELE M, Conroy G, Barron A, Marut D, et al
   Hemodynamic Effects of Continuous Intravenous Midazolam in Refractory Status Epilepticus.
   Clin Neuropharmacol. 2025;48:112-117.
   

   >> Share

   
   May 2025
4. OMERHODZIC I, Rovcanin B, Dzurlic A, Hodzic M, et al
   Efficacy and Safety of Oxcarbazepine as Monotherapy for Prevention of Epileptic Seizures in Patients With Supratentorial Brain Tumors: A Prospective Multicentric Study.
   Clin Neuropharmacol. 2025 May 9. doi: 10.1097/WNF.0000000000000639.
   

   >> Share

   
   
5. KIM HK, Kwack DW, Kim DW
   Two-Year Retention Rate and Clinical Usefulness of Eslicarbazepine Acetate in Epilepsy Patients.
   Clin Neuropharmacol. 2025;48:93-96.
   

   >> Share

   
   
6. ERTURK CETIN O, Algedik P, Akyuz G, Surmeli R, et al
   Minor/Major Congenital Malformations and Neurodevelopmental Outcomes in Children Prenatally Exposed to Levetiracetam, Lamotrigine, and Carbamazepine Monotherapy.
   Clin Neuropharmacol. 2025;48:61-66.
   

   >> Share

   
   February 2025
7. RALSTON MJ, Reed F, Osman A
   A Case of Post-Acute Severe Acute Respiratory Syndrome Coronavirus 2-Induced Focal Nonconvulsive Status Epilepticus With Impairment of Consciousness Initially Diagnosed as Anxiety.
   Clin Neuropharmacol. 2025 Feb 5. doi: 10.1097/WNF.0000000000000621.
   

   >> Share

   
   March 2024
8. TANTILLO G, Davis N, Granstein J, Yoo JY, et al
   Provider Experience With the Use of Ketamine for Refractory Status Epilepticus.
   Clin Neuropharmacol. 2024;47:37-43.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share